Picture: ELRIG

ELRIG – keeping connected

Melanie Leveridge takes over the lead of the European Laboratory Research & Innovation Group (ELRIG) UK to drive further collaboration between academia and biopharma industry.

The not-for-profit organisation ELRIG UK announced the election of Melanie Leveridge as Chair. Leveridge is considered a drug discovery expert. She is Head of Screening, Profiling and Mechanistic Biology UK, and Global Compound Management at GlaxoSmithKline (GSK), and will guide ELRIG in driving further collaboration and knowledge exchange between academic and biopharma industry thought-leaders, through the provision of scientific meetings and conferences on an open access basis. She said: “Now more than ever, it is important that we keep connected as a scientific community.” She succeeds Steve Rees, VP of Discovery Biology at AstraZeneca, who will be stepping down after four years as ELRIG Chair.

Since 2017, Leveridge has been an active ELRIG member, as Chair of the Science Strategy Workgroup, and as a member of the Board of Directors with overall accountability for the scientific content of the organisation's meetings.